

# James J Mahoney Iii

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7575487/publications.pdf>

Version: 2024-02-01

68  
papers

1,921  
citations

257450

24  
h-index

289244

40  
g-index

70  
all docs

70  
docs citations

70  
times ranked

2587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Educating for the Future: a Preliminary Investigation of Doctoral-Level Clinical Psychology Training Program's Implementation of Telehealth Education. Journal of Technology in Behavioral Science, 2022, 7, 351-357.	2.3	8
2	Deep brain stimulation for psychiatric disorders and behavioral/cognitive-related indications: Review of the literature and implications for treatment. Journal of the Neurological Sciences, 2022, 437, 120253.	0.6	3
3	High prevalence of co-occurring substance use in individuals with opioid use disorder. Addictive Behaviors, 2021, 114, 106752.	3.0	19
4	Frequency and perceived effectiveness of mental health providers' coping strategies during COVID-19. Current Psychology, 2021, 40, 5753-5762.	2.8	9
5	Deep brain stimulation of the nucleus accumbens/ventral capsule for severe and intractable opioid and benzodiazepine use disorder.. Experimental and Clinical Psychopharmacology, 2021, 29, 210-215.	1.8	12
6	Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review. Drug and Alcohol Dependence, 2021, 226, 108838.	3.2	15
7	Neuropsychologists' practice adjustments: The impact of COVID-19. Clinical Neuropsychologist, 2021, 35, 490-517.	2.3	13
8	Assessing Psychometrists' Practices to Inform Neuropsychological Services. Archives of Clinical Neuropsychology, 2021, 36, 693-701.	0.5	0
9	West Virginia's model of buprenorphine expansion: Preliminary results. Journal of Substance Abuse Treatment, 2020, 108, 40-47.	2.8	27
10	Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment. Journal of the Neurological Sciences, 2020, 418, 117149.	0.6	59
11	Something to despair: Gender differences in adverse childhood experiences among rural patients. Journal of Substance Abuse Treatment, 2020, 116, 108056.	2.8	16
12	Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program. Journal of the Neurological Sciences, 2020, 411, 116712.	0.6	13
13	A case report illustrating the effects of repetitive transcranial magnetic stimulation on cue-induced craving in an individual with opioid and cocaine use disorder.. Experimental and Clinical Psychopharmacology, 2020, 28, 1-5.	1.8	15
14	Mental Health Practitioners' Immediate Practical Response During the COVID-19 Pandemic: Observational Questionnaire Study. JMIR Mental Health, 2020, 7, e21237.	3.3	35
15	Substance Use Disorders: Cognitive Sequelae, Behavioral Manifestations, Neuroimaging Correlates, and Novel Interventions. , 2019, , 697-728.		2
16	Cognitive dysfunction in individuals with cocaine use disorder: Potential moderating factors and pharmacological treatments.. Experimental and Clinical Psychopharmacology, 2019, 27, 203-214.	1.8	29
17	A Forensic Case Report Involving Unequivocal Severe Brain Injury and Unequivocal Response Bias. Journal of Forensic Psychology Research and Practice, 2018, 18, 374-387.	0.5	0
18	The relationship between the Neuro-Quality of Life Depression and Anxiety Measures and the Personality Assessment Inventory in persons with epilepsy. Epilepsy and Behavior, 2017, 70, 145-149.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Electrocardiographic characteristics in individuals with cocaine use disorder. American Journal on Addictions, 2017, 26, 221-227.	1.4	4
20	Referring Providers's Preferences and Satisfaction with Neuropsychological Services. Archives of Clinical Neuropsychology, 2017, 32, 427-436.	0.5	17
21	The limited impact that cocaine use patterns have on neurocognitive functioning in individuals with cocaine use disorder. Journal of Psychopharmacology, 2017, 31, 989-995.	4.0	5
22	The relationship between premorbid IQ and neurocognitive functioning in individuals with cocaine use disorders.. Neuropsychology, 2017, 31, 311-318.	1.3	10
23	Treadmill exercise improves fitness and reduces craving and use of cocaine in individuals with concurrent cocaine and tobacco-use disorder. Psychiatry Research, 2016, 245, 133-140.	3.3	34
24	Relative Utility of Performance and Symptom Validity Tests. Archives of Clinical Neuropsychology, 2016, 31, 18-22.	0.5	23
25	Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder. International Journal of Neuropsychopharmacology, 2016, 19, pyv098.	2.1	13
26	Criterion Validity of the WAIS-IV Cognitive Proficiency Index (CPI). Clinical Neuropsychologist, 2015, 29, 777-787.	2.3	2
27	Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids. Drug and Alcohol Dependence, 2015, 153, 306-313.	3.2	28
28	Withdrawal Symptoms and Nicotine Dependence Severity Predict Virtual Reality Craving in Cigarette-Deprived Smokers. Nicotine and Tobacco Research, 2015, 17, 796-802.	2.6	33
29	The Interaction Between Medical Burden and Anticholinergic Cognitive Burden on Neuropsychological Function in a Geriatric Primary Care Sample. Archives of Clinical Neuropsychology, 2015, 30, 105-113.	0.5	6
30	A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disorders. Journal of Psychopharmacology, 2015, 29, 50-56.	4.0	63
31	Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. Psychiatry Research, 2015, 230, 44-49.	3.3	10
32	Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenetics and Genomics, 2015, 25, 296-304.	1.5	24
33	Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. International Journal of Neuropsychopharmacology, 2014, 17, 223-233.	2.1	18
34	A variant in <i>ANKK1</i> modulates acute subjective effects of cocaine: a preliminary study. Genes, Brain and Behavior, 2014, 13, 559-564.	2.2	16
35	Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 137-142.	4.8	17
36	Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 44-52.	4.8	4

#	ARTICLE	IF	CITATIONS
37	Short-term, low-dose varenicline administration enhances information processing speed in methamphetamine-dependent users. <i>Neuropharmacology</i> , 2014, 85, 493-498.	4.1	16
38	The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. <i>Psychiatry Research</i> , 2014, 219, 367-371.	3.3	37
39	Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: A randomized, double blind, placebo-controlled human laboratory study. <i>Drug and Alcohol Dependence</i> , 2014, 141, 72-78.	3.2	39
40	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 331-336.	2.1	195
41	The impact of self-reported life stress on current impulsivity in cocaine dependent adults. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 46, 113-119.	4.8	11
42	Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. <i>Neuropharmacology</i> , 2013, 64, 472-478.	4.1	49
43	The influence of smoking cigarettes on the high and desire for cocaine among active cocaine users. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 106, 132-136.	2.9	24
44	Effects of methamphetamine on the noradrenergic activity biomarker salivary alpha-amylase. <i>Drug and Alcohol Dependence</i> , 2013, 133, 759-762.	3.2	5
45	The relationship between lifetime stress and addiction severity in cocaine-dependent participants. <i>European Neuropsychopharmacology</i> , 2013, 23, 351-357.	0.7	18
46	Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine- and nicotine-dependent volunteers. <i>Addictive Behaviors</i> , 2013, 38, 1518-1526.	3.0	27
47	Neurocognitive effects following an overnight call shift on faculty anesthesiologists. <i>Acta Anaesthesiologica Scandinavica</i> , 2013, 57, 1051-1057.	1.6	18
48	Subjective and Cardiovascular Responses to Cocaine Differ in Cigarette Smokers versus Nonsmokers. <i>FASEB Journal</i> , 2013, 27, 659.17.	0.5	0
49	The Impact of Disulfiram Treatment on the Reinforcing Effects of Cocaine: A Randomized Clinical Trial. <i>PLoS ONE</i> , 2012, 7, e47702.	2.5	22
50	Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1241-1249.	2.1	22
51	Rivastigmine reduces "likely to use methamphetamine" in methamphetamine-dependent volunteers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 141-146.	4.8	27
52	d-Cycloserine administration does not affect neurocognition in concurrent cocaine- and nicotine-dependent volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 103, 403-407.	2.9	2
53	Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: Focus on dopamine, norepinephrine and glutamate. , 2012, 134, 260-277.		47
54	Noradrenergic $\alpha 1$ Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial. <i>PLoS ONE</i> , 2012, 7, e30854.	2.5	48

#	ARTICLE	IF	CITATIONS
55	Acute, low-dose methamphetamine administration improves attention/information processing speed and working memory in methamphetamine-dependent individuals displaying poorer cognitive performance at baseline. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 459-465.	4.8	22
56	The relationship between impulsivity and craving in cocaine- and methamphetamine-dependent volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 98, 196-202.	2.9	51
57	Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 99, 423-427.	2.9	9
58	Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. <i>Gender Medicine</i> , 2010, 7, 414-421.	1.4	41
59	Predictors of Cardiovascular Response to Methamphetamine Administration in Methamphetamine-Dependent Individuals. <i>American Journal on Addictions</i> , 2008, 17, 103-110.	1.4	8
60	Presence and Persistence of Psychotic Symptoms in Cocaine- versus Methamphetamine-Dependent Participants. <i>American Journal on Addictions</i> , 2008, 17, 83-98.	1.4	84
61	The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 89, 200-208.	2.9	45
62	Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 1037.	2.1	51
63	Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. <i>Psychiatry Research</i> , 2007, 152, 205-210.	3.3	19
64	A qualitative and quantitative review of cocaine-induced craving: The phenomenon of priming. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 593-599.	4.8	25
65	MDMA use and neurocognition: a meta-analytic review. <i>Psychopharmacology</i> , 2007, 189, 531-537.	3.1	111
66	Invariant mantling of growth cones by Schwann cell precursors characterize growing peripheral nerve fronts. <i>Glia</i> , 2006, 54, 424-438.	4.9	48
67	Role of N-cadherin in Schwann cell precursors of growing nerves. <i>Glia</i> , 2006, 54, 439-459.	4.9	71
68	A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. <i>Brain Research</i> , 2004, 1021, 209-218.	2.2	124